A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 464 participants.
Also called NCT05255094
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 464 participants
- Sponsor
- Registry
-
NCT05255094
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05255094. Randomized; quadruple masking; primary purpose treatment. Start 2021-11-03 (actual); primary completion 2022-06-22 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia
- Condition
- Hyperlipidemia
- Intervention (Biological)
- AK102
- Intervention (Biological)
- AK102
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Lead sponsor
- Akeso
Record details
- Record id
cardio:ct-nct05255094- Content hash
b2a34dbb05f398e8d353483f651274b097c9355cb2fac1c5449d089215761c6b